KYTX

4.2802.06%
CL

Christi L. Shaw

Executive Chairperson

Ms. Christi L. Shaw is Director of Kyverna Therapeutics, Inc. since September 14, 2024 and serves as Executive Chairperson since January 12, 2026. She serves as Member of Board of Advisors at Cellares Corporation since 2024. She serves as Director at ReAlta Life Sciences, Inc. since January 2024. She had been Chief Executive Officer of Kite Pharma, Inc. since July 2019 until March 2023. She served as Advisory Board Member at Concord Health Partners, LLC since joining on August 15, 2019. She was Senior Vice President of Eli Lilly &. Co. from April 3, 2017 until July 2019. She is the co-Founder of the More Moments More Memories Foundation to assist people with cancer and their caregivers. Ms. Shaw was President of Lilly Bio-Medicines at Eli Lilly and Company from April 3, 2017 until July 2019. Ms. Shaw served as an Executive Officer of Eli Lilly and Company (Lilly), a global healthcare company. Ms. Shaw has extensive senior leadership experience within the healthcare industry. Ms. Shaw has experience in the biopharmaceutical industry. Ms. Shaw is a renowned leader with deep experience providing commercial, financial, strategic, medical and operations leadership across the healthcare companies and biopharmaceutical industry. Ms. Shaw had been Independent Director of Avantor, Inc. since November 2018 until May 9, 2024 and Executive Board Member of the Biotechnology Industry Organization (BIO). She is an advisor to the Healthcare Businesswomen’s Association. Ms. Shaw served as President of Novartis Corporation since April 2014. Ms. Shaw served as President and US Country Head of Novartis Pharmaceuticals Corporation since April 2014 to 2016. She served as North American Region Head of Novartis Oncology at Novartis Pharmaceuticals Corporation from 2010 to 2014. She started her career at Lilly in 1989. Ms. Shaw joined Novartis Oncology in July 2010, overseeing all commercial operations for the US and Canada. She has strong capabilities across Marketing, Sales, BD&L, Pipeline Development and Business Strategy. Ms. Shaw is also a Member of Gilead’s senior leadership team. Prior to Novartis in 2010, she was at Johnson & Johnson as Vice President, New Business Development & Strategic Analytics for Ethicon. Ms. Shaw was responsible for leading Ethicon’s franchise-wide business development initiatives, including licensing and acquisition and technology assessment, as well as the company’s business information and analytics capabilities. She serves as Member of Biopharma Advisory Board at Ginkgo Bioworks Holdings, Inc. since January 8, 2024. Ms. Shaw spent two years as Vice President, Worldwide Marketing, Ethicon Products, where she worked with R&D to accelerate the pipeline, resulting in six product launches. She joined Johnson & Johnson in 2002 at Janssen Pharmaceuticals. During her tenure in that Corporation, she transitioned through a number of positions with increasing responsibility within Janssen Psychiatry, Ortho Women’s Health & Urology and McNeil Pediatrics primarily within sales, strategic marketing and business development. She joined the device and diagnostic division at Ethicon in 2007. She started her career in Pharmaceuticals at Eli Lilly and Company. She serves as an Independent Director of Beam Therapeutics Inc. since December 2023. She serves as Independent Director of ReAlta Life Sciences. Ms. Shaw’s unwavering commitment to addressing the evolving needs of patients in collaboration with healthcare professionals, advocacy groups, payors and policy makers has garnered her numerous accolades throughout her career, most notably a 2019 Women in Oncology Award (PRIMO) and a 2016 Lifetime Achievement Award (Eye for Pharma), among others. Ms. Shaw has Completed MBA from the University of Wisconsin Oshkosh and a BBA in Marketing from Iowa State University.

Positions